Medetomidine Emerges as New Threat in Fentanyl Supply, Challenging Overdose Response

A veterinary sedative up to 300 times more potent than xylazine is rapidly spreading through the nation's illicit opioid supply, forcing emergency departments and addiction specialists to adapt protocols for a drug that can cause life-threatening withdrawal and doesn't show up on standard toxicology screens.

The American Academy of Family Physicians published guidance for clinicians this month warning that medetomidine—a synthetic alpha-2 adrenoreceptor agonist used to sedate large animals—has become ubiquitous in several major metropolitan areas and is likely spreading to others. The veterinary drug, which first appeared in Maryland's illicit supply in 2022, has been linked to overdose clusters in Chicago, Philadelphia, and Pittsburgh and detected in California, Colorado, Missouri, Pennsylvania, and Illinois.

Dr. Judy Chertok and Dr. Navid Roder, authors of the AAFP editorial, emphasize that rapid changes in the drug supply create profound clinical impacts that primary care physicians can no longer afford to ignore. "Medetomidine does not appear to cause the wounds typically seen with xylazine use," they write, "but xylazine and medetomidine are not included in standard urine drug testing. The levels of adulterants in the drug supply can fluctuate, causing unexpected intoxication and withdrawal."

From Animal Medicine to Street Drug

Medetomidine received FDA approval in 1996 for veterinary use—specifically to calm anxious dogs before procedures. Like xylazine ("tranq"), which has been mixed into opioids since 2001 to intensify euphoric effects, medetomidine is now being added to fentanyl by suppliers seeking to prolong the short-lived high of synthetic opioids. But medetomidine is far more potent: at therapeutic doses in animals, it's up to 300 times stronger than xylazine at binding alpha-2 receptors in the central nervous system.

The drug is related to dexmedetomidine, a medication commonly used in intensive care units to sedate and calm patients on ventilators. That pharmaceutical cousin offers a hint of what medical teams are now encountering on the street: profound sedation, unpredictable blood pressure swings, and withdrawal syndromes that can escalate to medical emergencies within hours.

According to the Centers for Disease Control and Prevention's May 2025 Morbidity and Mortality Weekly Report, Chicago experienced a cluster of overdoses involving medetomidine in May 2024 that prompted the Chicago Department of Public Health to issue two health alerts within weeks. Medical personnel were advised to inform poison control of suspected opioid overdoses that appeared atypical and to pursue toxicology testing through specialized programs like DEA TOX, which screens for new psychoactive substances not included in routine panels.

Philadelphia saw a similar surge. The city's health department reported in a May 2025 CDC report that the number of patients presenting to emergency departments for withdrawal symptoms more than doubled after medetomidine entered the local fentanyl supply in late 2024. Dr. Sam Stern, an addiction medicine specialist at Temple University Hospital, told researchers that managing medetomidine withdrawal has become routine in his practice—a situation he characterized as historically unprecedented.

The Withdrawal Crisis

While medetomidine intoxication resembles other alpha-2 agonist overdoses—hypotension, bradycardia, prolonged sedation—it's the withdrawal syndrome that has caught clinicians off guard.

Symptoms can begin within hours of last use, peaking at 18 to 36 hours. Unlike typical opioid withdrawal, which is intensely uncomfortable but rarely dangerous, medetomidine withdrawal can cause profound tachycardia, severe hypertension, intractable vomiting, and altered mental status. Vital signs can swing wildly: from hypotension and slow heart rate (direct alpha-2 effects) to hypertension and rapid pulse a few hours later as withdrawal sets in.

Some patients require ICU-level monitoring due to neurologic changes, inability to tolerate oral medications, or hypertensive emergencies with end-organ damage—including posterior reversible encephalopathy syndrome (PRES) and non-ST elevation myocardial infarction (heart attack). Pennsylvania's Department of Health issued an advisory in June 2025 noting that emergency department visits for medetomidine-related complications had surged and that hospitalization rates were climbing.

Treatment involves escalating doses of alpha-2 agonist medications: oral or transdermal clonidine, oral tizanidine (a muscle relaxant with alpha-2 activity), oral guanfacine (typically used for ADHD and hypertension), and in severe cases, intravenous dexmedetomidine—which itself requires ICU monitoring. Doses often exceed typical prescribing limits, and optimal tapering strategies remain unknown. Some patients need days to weeks of carefully managed reduction.

Severe nausea and vomiting are nearly universal and can be treated with ondansetron, prochlorperazine, or olanzapine. But treating medetomidine withdrawal doesn't replace treating opioid withdrawal: patients still need medications for opioid use disorder (buprenorphine, methadone, naltrexone) alongside the alpha-2 agonist regimen.

The AAFP authors note that the adage "opioid withdrawal is uncomfortable but not dangerous" no longer holds in the context of a contaminated drug supply. "People who primarily use opioids can have dangerous withdrawal from nonopioid contaminants," they warn.

Naloxone Still Works—But It's Not Enough

For overdose response, naloxone remains the foundation of treatment even when medetomidine is suspected. But because medetomidine causes sedation and respiratory suppression through a different mechanism than opioids, patients may not fully wake up after naloxone administration. Ongoing airway protection and supportive care may be required for hours after the opioid component is reversed.

This creates a clinical dilemma for bystanders and first responders accustomed to seeing people regain consciousness within minutes of naloxone administration. If someone doesn't "snap out of it," it doesn't mean naloxone failed—it means the overdose involves sedatives that naloxone can't counteract. The person still needs emergency medical care and monitoring, even if breathing has stabilized.

Why Medetomidine Is Replacing Xylazine

Xylazine became a public health flashpoint in 2023 after it was detected in more than 90 percent of Philadelphia's drug supply and linked to horrific necrotic skin wounds that left users with exposed bone and tissue damage requiring amputations. The Drug Enforcement Administration designated xylazine an "emerging threat" in March 2023, and several states moved to schedule it as a controlled substance, restricting veterinary access and increasing penalties for illicit distribution.

Medetomidine appears to be filling the gap. According to the DEA's October 2024 National Drug Threat Assessment, submissions of medetomidine and dexmedetomidine to federal crime labs increased significantly in 2024. The agency noted that both drugs have "the potential to be supplements to or replacements for xylazine in terms of mixing with illicit opioids."

Importantly, medetomidine does not cause the tissue-destroying wounds associated with xylazine—a fact that may make it more appealing to suppliers and users alike. But the absence of visible harm doesn't mean the drug is safer. The withdrawal syndrome alone poses life-threatening risks that xylazine rarely produced.

What Physicians and Communities Can Do

The AAFP guidance urges physicians working with populations that use illicit drugs to stay informed about local drug supply changes. "Physicians should consider reaching out to the local public health department and social services organizations to learn about real-time changes in the local drug supply," Chertok and Roder write.

Drug checking services—which use test strips or laboratory analysis to identify contaminants—are increasingly available and provide early detection of new adulterants. Some communities have implemented mail-in testing programs or drop-in sites where people can anonymously submit samples for analysis. These services not only protect individual users but also generate surveillance data that alerts public health agencies to emerging threats.

In settings where medetomidine contamination is widespread, some clinicians are proactively prescribing oral alpha-2 agonists (like clonidine) when initiating buprenorphine or methadone, anticipating that patients will experience alpha-2 withdrawal alongside opioid withdrawal. Counseling patients on which symptoms should prompt emergency care—severe headache, chest pain, vomiting that prevents medication adherence—can help prevent deterioration at home.

The Broader Pattern

Medetomidine's rise follows a familiar trajectory in the opioid crisis: a new adulterant appears, overdoses spike, public health agencies scramble to respond, and by the time interventions are in place, the drug supply has evolved again.

Xylazine emerged in the early 2000s, surged in Puerto Rico around 2010, spread to Philadelphia by the late 2010s, and became a national crisis by 2023. Medetomidine was first detected in Maryland in 2022, spread to multiple states by 2023, and caused overdose clusters in major cities by early 2025. The pattern suggests that what's happening in Chicago, Philadelphia, and Pittsburgh today could be widespread across the country within months.

This cycle is driven by economic incentives: fentanyl's potency allows suppliers to ship massive doses in small packages, but fentanyl's high is short-lived. Adding sedatives like xylazine or medetomidine extends the duration, increasing perceived value. When one adulterant becomes difficult to source or legally risky, suppliers simply switch to another.

The result is a moving target for harm reduction and treatment. People who use drugs never know exactly what they're taking. Clinicians treating overdose or withdrawal can't rely on patient history alone—they must assume novel contaminants are present and prepare for atypical presentations.

Overdose Deaths Declining—But the Drug Supply Keeps Evolving

Medetomidine's emergence comes at a paradoxical moment: overdose deaths have declined nearly 40 percent from their 2023 peak, reaching the lowest levels in six years. Researchers attribute much of that decline to weakened fentanyl potency—DEA seizure data show purity dropping from 25 percent to 11 percent as suppliers began cutting product with fillers.

But the appearance of medetomidine, alongside stimulant-involved overdoses and other novel synthetics, reminds public health experts that progress is fragile. Lower overdose deaths don't mean the drug supply is safer—they may simply reflect a temporary disruption in supply chains or the fact that users have adapted by carrying naloxone and using with others present.

Medetomidine threatens to reverse progress. If people using drugs can't reliably reverse overdoses with naloxone, or if withdrawal becomes so severe that they avoid treatment, the tools that have driven recent declines lose effectiveness.

A Call for Sustained Investment

Medetomidine is unlikely to be the last veterinary sedative diverted into the drug supply. Dexmedetomidine—the FDA-approved human formulation—is also appearing in illicit samples, and other alpha-2 agonists could follow.

The AAFP guidance concludes with a reminder that the most important intervention for opioid use disorder remains medication treatment—buprenorphine, methadone, or naltrexone. "Treating medetomidine withdrawal safely and proactively can support patients in the transition to MOUD," the authors write. But that requires clinicians who are trained to recognize novel withdrawal syndromes, hospitals willing to admit patients for observation, and insurance coverage that doesn't balk at extended ICU stays for "just" substance use.

Patients who continue using drugs should be educated about medetomidine's risks and encouraged to access drug checking services where available. Harm reduction messaging—using naloxone, not using alone, accessing sterile syringes, testing for hepatitis C and HIV—remains essential even as the specifics of the drug supply shift.

Medetomidine is another chapter in a crisis that has claimed more than a million American lives since 1999. Whether it becomes as widespread as xylazine or fades as supply chains adapt remains to be seen. What's certain is that the people most affected—those who use drugs, the clinicians who care for them, and the communities navigating this crisis—deserve resources, information, and systems capable of responding to threats as they emerge, not years after the damage is done.